| First Author | Xie Z | Year | 2022 |
| Journal | Aging Cell | Volume | 21 |
| Issue | 3 | Pages | e13565 |
| PubMed ID | 35181976 | Mgi Jnum | J:322941 |
| Mgi Id | MGI:7257081 | Doi | 10.1111/acel.13565 |
| Citation | Xie Z, et al. (2022) Microglial cathepsin E plays a role in neuroinflammation and amyloid beta production in Alzheimer's disease. Aging Cell 21(3):e13565 |
| abstractText | Regulation of neuroinflammation and beta-amyloid (Abeta) production are critical factors in the pathogenesis of Alzheimer's disease (AD). Cathepsin E (CatE), an aspartic protease, is widely studied as an inducer of growth arrest and apoptosis in several types of cancer cells. However, the function of CatE in AD is unknown. In this study, we demonstrated that the ablation of CatE in human amyloid precursor protein knock-in mice, called APP(NL-G-F) mice, significantly reduced Abeta accumulation, neuroinflammation, and cognitive impairments. Mechanistically, microglial CatE is involved in the secretion of soluble TNF-related apoptosis-inducing ligand, which plays an important role in microglia-mediated NF-kappaB-dependent neuroinflammation and neuronal Abeta production by beta-site APP cleaving enzyme 1. Furthermore, cannula-delivered CatE inhibitors improved memory function and reduced Abeta accumulation and neuroinflammation in AD mice. Our findings reveal that CatE as a modulator of microglial activation and neurodegeneration in AD and suggest CatE as a therapeutic target for AD by targeting neuroinflammation and Abeta pathology. |
